The biopharma industry stands at a transformative juncture as it reflects on the achievements of the past year and anticipates the evolving client requirements that will shape 2025 and beyond. Key insights from Subodh Deshmukh, CEO of Aragen Bioscience, highlight the crucial areas of focus for
Thermo Fisher Scientific is taking bold steps toward revolutionizing drug development through its innovative Accelerator Drug Development program. This strategy aims to streamline the complex process from preclinical stages to commercialization by integrating its contract research organization
The potential breakthrough in treating liver cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) has come from a recent study by Akero Therapeutics. Efruxifermin, an experimental drug, has shown significant promise in reversing liver damage in patients suffering from this
Precision Medicine (PM), also known as personalized medicine, tailors medical treatments to individual characteristics, specifically focusing on genetic profiles. The intersection of PM and Artificial Intelligence (AI) is accelerating the adoption and effectiveness of precision medicine, addressing
3D bioprinting is an innovative technology that promises to revolutionize cancer research and treatment by providing more accurate and complex models of tumor tissue. This advancement is particularly significant in the study of cancers involving the BRCA1 gene. Tumor modeling with 3D bioprinting
The transformative impact of a historic AI infrastructure investment on the drug discovery and healthcare sectors is becoming increasingly evident. This $500 billion investment, spearheaded by Stargate—a collaborative venture between OpenAI, SoftBank, and Oracle—aims to fast-track breakthroughs in p
